Compounds and compositions for delivering active agents
View Patent ↗The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.
1. A delivery agent compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. The delivery agent compound of claim 1 , wherein the delivery agent is
or a pharmaceutically acceptable salt thereof.
3. The delivery agent compound of claim 1 , wherein the delivery agent is
or a pharmaceutically acceptable salt thereof.
4. The delivery agent compound of claim 1 , wherein the delivery agent is
or a pharmaceutically acceptable salt thereof.
5. The delivery agent compound of claim 1 , wherein the delivery agent is
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising
(A) a therapeutically effective amount of a biologically active agent;
(B) at least one compound selected from the group consisting of
and pharmaceutically acceptable salts thereof, and
(C) a pharmaceutically acceptable excipient,
wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof.
7. The pharmaceutical composition of claim 6 , wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, GLP-1, heparin, recombinant human growth hormone, argatroban, and any combination thereof.
8. The pharmaceutical composition of claim 6 , wherein the biologically active agent is argatroban.
9. The pharmaceutical composition of claim 6 , wherein the biologically active agent is insulin.
10. The pharmaceutical composition of claim 6 , wherein the biologically active agent is human growth hormone.
11. The pharmaceutical composition of claim 6 , wherein the growth hormone is human growth hormone, recombinant human growth hormone (rhGH), bovine growth hormone or porcine growth hormone.
12. The pharmaceutical composition of claim 6 , wherein the calcitonin is salmon calcitonin, eel calcitonin or human calcitonin.
13. The pharmaceutical composition of claim 6 , wherein the insulin is porcine insulin, bovine insulin, human insulin or human recombinant insulin.
14. The pharmaceutical composition of claim 6 , wherein the heparin is unfractionated heparin, low molecular weight heparin, very low molecular weight heparin or ultra low molecular weight heparin.
15. The pharmaceutical composition of claim 6 , wherein the insulin-like growth factor is IGF-I.
16. A dosage unit form comprising a pharmaceutical composition of claim 6
17. The dosage unit form of claim 16 , wherein the dosage unit form is a tablet or capsule.
18. A pharmaceutical composition comprising
(A) a therapeutically effective amount of a biologically active agent;
(B) a compound selected from:
and pharmaceutically acceptable salts thereof; and
(C) a pharmaceutically acceptable excipient;
wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban, and any combination thereof.
19. A pharmaceutical composition comprising
(A) a therapeutically effective amount of a biologically active agent;
(B) a compound selected from:
and pharmaceutically acceptable salts thereof; and
(C) a pharmaceutically acceptable excipient;
wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban; and any combination thereof.
20. A pharmaceutical composition comprising
(A) a therapeutically effective amount of a biologically active agent;
(B) a compound selected from:
and pharmaceutically acceptable salts thereof; and
(C) a pharmaceutically acceptable excipient;
wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof.
21. A pharmaceutical composition comprising
(A) a therapeutically effective amount of a biologically active agent;
(B) a compound selected from:
and pharmaceutically acceptable salts thereof; and
(C) a pharmaceutically acceptable excipient;
wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof.
22. The composition according to claim 20 , wherein the biologically active agent is selected from calcitonin, insulin, PTH, GLP-1, heparin, argatroban; and any combination thereof.
23. The composition according to claim 21 , wherein the biologically active agent is selected from calcitonin, insulin, PTH, GLP-1, heparin, argatroban; and any combination thereof.